Evaluation of Increased Absorption of a Curcumin Emulsion (CurQ+) in Healthy Volunteers

NCT ID: NCT04103788

Last Updated: 2021-12-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-27
• Study Completion Date: 2018-12-13

Brief Summary

This study is intended to evaluate the comparative effects of direct analysis of serum samples versus pre-treatment with enzymatic hydrolysis in split samples obtained from dosing with a highly absorbed curcumin emulsion product that is commercially available as BIOCURC.

Detailed Description

When curcumin is absorbed by the body, it is primarily found in the bloodstream as curcumin glucuronide (C-gluc) and curcumin sulfate (C-SO4) metabolites. Traditionally bioavailability studies have performed an enzymatic hydrolysis pre-treatment of serum samples with both a glucuronidase and a sulfatase enzyme in order to produce free curcumin for analysis via HPLC. In subsequent years, standards have become available for the metabolites (C-gluc & C-SO4) that make it possible to determine these compound levels directly in serum samples using HPLC-MS-MS. Initial pilot work had indicated that enzymatic hydrolysis was producing falsely elevated results for bioavailability. We wanted to evaluate this in a more formal setting.

Conditions

Bioavailability

Keywords

Bioavailability; Absorption

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

95% Curcuminoid Powder

Curcumin powder standardized to \>95% curcuminoids, single dose, used to determine standard absorptivity of unformulated powder.

Group Type: ACTIVE_COMPARATOR

95% Curcuminoid Powder

Intervention Type: DIETARY_SUPPLEMENT

1200 mg curcuminoids

CurQ+

Highly absorbed curcumin coconut oil emulsion, single dose, used to produce serum samples for analytical comparison of sample preparation methodologies.

Group Type: EXPERIMENTAL

CurQ+

Intervention Type: DIETARY_SUPPLEMENT

400 mg curcuminoids + coconut oil + polysorbate

Interventions

95% Curcuminoid Powder

1200 mg curcuminoids

Intervention Type: DIETARY_SUPPLEMENT

CurQ+

400 mg curcuminoids + coconut oil + polysorbate

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Male or Female subjects must be 21-75 years of age at the time of screening.

a. Female subjects must agree to use one of the following medically acceptable contraceptive methods from the Screening visit (unless otherwise stated) through the End of Study (EOS) visit. Acceptable methods include: abstinence, same-sex partner, double barrier (condom, diaphragm, or cervical cap with spermicidal foam, gel, or cream), bilateral tubal ligation, hysterectomy, bilateral oophorectomy; intrauterine device (IUD) with or without hormones in place or hormonal contraception (oral, injectable, implantable, transdermal, or vaginal) used consecutively for at least 3 months prior to the Screening visit; vasectomized partner or bilateral insertion of Essure® implants for at least 6 months prior to the Screening visit; or postmenopausal status with amenorrhea (no menses) for at least 1 year prior to the Screening visit.

2. Subjects must be willing to refrain from consuming the spice turmeric or any dietary supplements containing turmeric or curcumin (except for the study products) throughout the entire study.

3. Subjects must be available for and willing to attend all evaluation visits.

4. Subjects must be able and willing to give informed consent.

5. Subjects participating in prior studies evaluating CurQ+® or curcumin can participate in the present study so long as they are not currently taking a curcumin containing supplement (including turmeric) and have not done so for 14 days prior to screening.

Exclusion Criteria

1. Subject is currently receiving therapy with remission-inducing drugs (i.e. methotrexate, TNF biologics, etc.), immunosuppressive drugs (i.e. corticosteroids, transplantation medications, etc.).

2. Subjects must not have taken turmeric- or curcumin-containing dietary supplements within 14 days prior to screening evaluation.

3. Subject has been diagnosed with any clinically significant confounding metabolic disease or condition that would interfere with the study evaluation, as judged by the clinical investigator (slow or fast metabolism resulting from hypo- or hyper-thyroidism, Cushing's Syndrome, Diabetes (except for fully resolved gestational diabetes), etc.) or any conditions that would affect absorption in the GI tract (i.e. inflammatory bowel disease, celiac disease, Behçet's Syndrome, systemic sclerosis, etc.).

4. Subject has known allergy to any of the investigational products, including but not limited to turmeric, curcumin, coconut or coconut oil. If any subject becomes sensitive during the study, they will immediately be excluded from continuing in the study.

5. Subject's body weight is greater than 300 pounds (136.1 kg) at the time of Screening.

6. Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of the first baseline evaluation.

7. Pregnant and/or breastfeeding women, or women who intend to become pregnant during the course of the study.

8. Subject has a history or positive test result of HIV, hepatitis B or hepatitis C.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

ESM Technologies, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kevin J. Ruff, Ph.D.

Role: STUDY_DIRECTOR

Stratum Nutrition

Locations

QPS Bio-Kinetic

Springfield, Missouri, United States

Countries

United States

References

Stohs SJ, Chen CYO, Preuss HG, Ray SD, Bucci LR, Ji J, Ruff KJ. The fallacy of enzymatic hydrolysis for the determination of bioactive curcumin in plasma samples as an indication of bioavailability: a comparative study. BMC Complement Altern Med. 2019 Nov 4;19(1):293. doi: 10.1186/s12906-019-2699-x.

Reference Type: RESULT

PMID: 31684927 (View on PubMed)

Related Links

https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-019-2699-x

Evaluation of Increased Absorption of a Curcumin Emulsion (BIOCURC) in Healthy Volunteers

Other Identifiers

ESM-CLN#2018T01

Identifier Type: -

Identifier Source: org_study_id